glp-1 medications approved for type 2 diabetes 2025 Drugs and 1 Diabetes: Less Insulin, Better Time in Range — What the Evidence GLP-1: A Breakthrough in Diabetes

In SUSTAIN trials, semaglutide had higher rates of GI side effects than dulaglutide, but most were mild to moderate and occurred during dose escalation

Since BED and BN have high comorbidity with depressive, bipolar and other mental disorders, as well as increased suicidal behavior, the safety profile of GLP-1RAs gives them a key advantage over existing pharmacotherapy options for treating BED

Retrieved from Ozsoy, S., Besirli, A., Abdulrezzak, U., et al

High cortisol levels can interfere with appetite control and glucose metabolism

Liraglutide and polycystic ovary syndrome: is it only a matter of body weight

Furthermore, LCA treatment caused onion-skin lesions in all DKO mice, while only 63% of the NT-DKO and 50% of the DCA-DKO mice developed this condition